The European Commission has published the fifth Joint Clinical Assessment (JCA), covering camizestrant (Etcamah) for the treatment of breast cancer. The assessment was prepared under the lead of Austria and Belgium within the framework of the EU-HTA Regulation. The national AMNOG procedure for camizestrant has not yet started.